JUN 18, 2016 11:29 AM PDT

FDA Approves At-Home Stomach Pump for Obesity Treatment

WRITTEN BY: Xuan Pham
The U.S. Food and Drug Administration just approved a new line of treatment for obese patients who struggle with the conventional non-surgerical weight-loss therapy. The newly approved device, named AspireAssist, involves a tube connected to the stomach that will drain a small amount of digested food after every meal. In effect, the device resembles a carefully controlled stomach pump, which has incited fierce criticisms amongst health experts.
   AspireAssist
 "The AspireAssist approach helps provide effective control of calorie absorption, which is a key principle of weight management therapy," said William Maisel, deputy director for science and chief scientist in the FDA's Center for Devices and Radiological Health.
 
Indeed, the AspireAssist’s success is through preventing the body from absorbing 100 percent of the foods the patient ingests. It starts with the surgeon placing a tube in the stomach. Connected to this tube is a port valve that’s flushed against the abdomen, on the outside of the body. Then after every meal, the patient drains out part of the stomach’s contents via an external connector to the port valve.
 
In clinical trials, the device demonstrated a 30 percent reduction in the calories absorbed by patients. Furthermore, of the 111 patients treated with AspireAssist, the average weight loss was 12.1 percent of their total body weight. This is significantly higher than the 3.6 percent lost in the control group who only received lifestyle therapy.
 
To help patients stay on track and prevent abuse of the device, makers have put safety mechanisms in place. For example, the device is programmed to stop working after 115 cycles, which equates to about 5 to 6 weeks of therapy. This means that doctors are closely monitoring patients to ensure proper use. In addition, this safety measure makes sure that the device is checked frequently for infections and other complications.
 
Nevertheless, it’s not enough to just be outfitted with the AspireAssist device. For patients to achieve healthy weight loss and maintain their progress, physicians agree that counseling and behavioral therapies are not optional. "Patients need to be regularly monitored by their health care provider and should follow a lifestyle program to help them develop healthier eating habits and reduce their calorie intake," said Maisel.
 
Not everyone who desires weight loss will be eligible for the AspireAssist. The device is only intended to help those who are over 22 years old, and are clinically obese, as defined by having a body mass index of 35 to 55. They must also have demonstrated history of failed weight loss via conventional methods that didn’t involve surgery.
 
Of course, as with any surgical procedure, the AspireAssist is not without risks. But for patients who need this help, doctors and the FDA agree that the benefits of weight loss exceed the risks of the procedure. However, critics of the device have gone as far as calling this a “bulimia machine” and wondered whether an at-home stomach pump is actually going a step too far.

Additional source: FDA release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
DEC 04, 2019
Immunology
DEC 04, 2019
Predicting Death with Clinical Immune Indicators
Immune and inflammation status could help doctors predict which individuals are most at-risk for death. Results from a n ...
JAN 28, 2020
Clinical & Molecular DX
JAN 28, 2020
Protein complex discovered as first biomarker of PTSD
  Researchers at the Centre for Addiction and Mental Health (CAMH) and the Canadian Institutes of Health Research ( ...
JAN 11, 2020
Neuroscience
JAN 11, 2020
Molecular Therapy to Self-Repair Nerve Cells
Neurodegenerative diseases such as Multiple Sclerosis (MS), Alzheimer's, and Huntington's Disease are predicated ...
APR 22, 2020
Clinical & Molecular DX
APR 22, 2020
Microneedle Skin Patch Collects Bodily Fluids for On-patch Diagnostic Testing
The collection of blood for diagnostic tests is common practice in clinical settings. However, technicians often need to ...
APR 29, 2020
Clinical & Molecular DX
APR 29, 2020
Saliva is Preferable to Deep Nasal Swabs for COVID-19 Testing
The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Incre ...
MAY 07, 2020
Clinical & Molecular DX
MAY 07, 2020
An 8 Minute DNA Test For Salmonella
Australian researchers have created a sensitive, super-fast test for five different serotypes of Salmonella which could ...
Loading Comments...